

Immune Biologics, Inc.
4835 East Cactus Road, Suite 334
Phoenix, AZ 85254

Contact: David L. Bergsma, President
Tel: 480-773-6020 x107
Mobile: 602-501-7590
Email: bioco@aol.com

FOR IMMEDIATE RELEASE

**KEY MEDICAL JOURNAL PUBLISHES NEW STRATEGY
AGAINST DRUG RESISTANT GERMS**
83% Survival Rate against MRSA in Study

December 29, 2006, Phoenix, AZ The proliferation of bacteria that have grown resistant to even the newest antibiotics poses a new and very dangerous threat to public health. The results of treating infected mice in a double blind study at the University of Arizona with Bioengineered Lacteal Complex (BLC) is published as "*A Pilot Study of an anti-MRSA Bio-Engineered Lacteal Complex (anti-MRSA BLC) in a Murine Septicemia Model*" co-authored by Jesse A. Stoff, MD, David E. Nix, MD and D.W. DeYoung, DVM in the new issue of the journal "*Immunopharmacology and Immunotoxicology*" released on December 29, 2006. In the face of this evolving threat an Arizona company, Immune Biologics, Inc., has acquired rights for the development and use of BLC's from the research group Sixty-Eight, LLC headed by Jesse A. Stoff, MD. BLC's are derived from the milk of dairy cows.

The Company's BLC is described as offering distinct advantages over traditional antibiotics and other strategies and paradigms for the treatment of infectious disease. BLC's use the immune system to launch their response, do not attack non-pathogenic organisms, can be used as a preventative strategy, can be used on multiple occasions without loss of efficacy with great safety, do not compromise the immune function of the user and perhaps most importantly they can be developed and brought to market in timelines as short as a few weeks. The first product, for the treatment of MRSA (Methicillin-resistant Staphylococcus aureus), is sorely needed by healthcare workers and patients worldwide. The Company, in conjunction with Biologics Consulting Group, LLC, Toxikon, Inc. and the University of Arizona is currently collaborating for development funding with the United States Department of Defense, seeking venture capital and preparing for presentation to the United States Food and Drug Administration.

Specialized BLC's are being developed under rights acquired by Immune Biologics, Inc. of Phoenix, Arizona. For further information contact David L. Bergsma at 480-773-6020, x107.

If you'd like more information about this topic or to schedule an interview with Jesse A. Stoff MD or David L. Bergsma please call 480-773-6020 x107 or email bioco@aol.com.